A systematic review of the evidence for medical marijuana in psychiatric indications

Journal of Clinical Psychiatry

Volumn 77, Issue 8, 2016, Pages 1050-1064

  Wilkinson, Samuel T ^a,b   Radhakrishnan, Rajiv ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRONABINOL; ENDOCANNABINOID; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; TETRAHYDROCANNABINOLIC ACID; CANNABINOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ANXIETY DISORDER; ATTENTION DISTURBANCE; CACHEXIA; CANCER RISK; CANNABIS ADDICTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; COUGHING; DEMENTIA; DISORIENTATION; DIZZINESS; DRIVING ABILITY; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; EVIDENCE BASED MEDICINE; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; INTOXICATION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MENTAL INSTABILITY; MOUTH PAIN; MUCOSAL DISEASE; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NAUSEA; NEUROTRANSMITTER RELEASE; NIGHTMARE; PARANOIA; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SPASTICITY; SYSTEMATIC REVIEW; THROAT IRRITATION; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING; WEAKNESS; WITHDRAWAL SYNDROME; XEROSTOMIA; MENTAL DISORDERS; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA;

CANNABINOIDS; HUMANS; MEDICAL MARIJUANA; MENTAL DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84989288155     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15r10036     Document Type: Review

References (76)

1. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1010 PubMed.
2. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1097 PubMed.
3. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines, 1: introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026 PubMed.
4. ElSohly MA, Ross SA, Mehmedic Z, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45(1):24-30. doi:10.1520/JFS14636J PubMed.
5. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-Terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. doi:10.1/j.1476-5381.201.01238.x PubMed.
6. Galal AM, Slade D, Gul W, et al. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Patents CNS Drug Discov. 2009;4(2):112-136. doi:10.2174/1574890978453031 PubMed.
7. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64(1):21-47. doi:10.146/anurev-psych-1301-143739 PubMed.
8. Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24(1):51-64. doi:10.1016/j.euroneuro.2013.1.02 PubMed.
9. Davis WM, Hatoum NS. Neurobehavioral actions of cannabichromene and interactions with Δ9-Tetrahydrocannabinol. Gen Pharmacol. 1983;14(2):247-252. doi:10.1016/0306-3623(83)904-6 PubMed.
10. Valdeolivas S, Navarrete C, Cantarero I, et al. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015;12(1):185-199. doi:10.107/s131-014-0304-z PubMed.
11. Farrimond JA, Whalley BJ, Williams CM. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology (Berl). 2012;223(1):117-129. doi:10.107/s0213-012-2697-x PubMed.
12. Rey AA, Purrio M, Viveros MP, et al. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. 2012;37(12):2624-2634. doi:10.1038/np.2012.123 PubMed.
13. Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology, LXXIX: cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588-631. doi:10.124/pr.10.0304 PubMed.
14. Marrs WR, Blankman JL, Horne EA, et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci. 2010;13(8):951-957. doi:10.1038/n.2601 PubMed.
15. Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Δ9-Tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry. 2002;35(2):57-61. doi:10.105/s-202-25028 PubMed.
16. Muller-Vahl KR, Schneider U, Prevedel H, et al. Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry. 2003;64(4):459-465. doi:10.408/JCP.v64n0417 PubMed.
17. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorderrelated insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559-564. doi:10.1097/JCP.0180.
18. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84-88. doi:10.1/j.175-5949.208.071.xPubMed.
19. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-Associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. PubMed.
20. Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral Δ9-Tetrahydrocannabinol in chronic post-Traumatic stress disorder. Clin Drug Investig. 2014;34(8):587-591. doi:10.107/s40261-014-0212-3 PubMed.
21. Mashiah M. Medical Cannabis as treatment for chronic combat PTSD: promising results in an open pilot study. Patients Out of Time Conference. 2012; Tucson, AZ.
22. Reznik I. Medical marijuana/cannabis use in patients with post-Traumatic stress disorder. The International Conference on Integrative Medicine. 2011; Jerusalem, Israel.
23. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(9):913-919. doi:10.102/(SICI)109-16(19709)12:9<913:AID-GPS63>3.0.CO;2-D PubMed.
24. Walther S, Mahlberg R, Eichmann U, et al. Delta-9-Tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185(4):524-528. doi:10.107/s0213-06-0343-1 PubMed.
25. Walther S, Schupbach B, Seifritz E, et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31(2):256-258. doi:10.1097/JCP.0b013e31820e861c PubMed.
26. Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22(4):415-419. doi:10.1016/j.jagp.2012.1.02 PubMed.
27. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev. 2009;(4):CD006565. PubMed.
28. Muller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 1998;98(6):502-506. doi:10.1/j.160-047.198.tb10127.x PubMed.
29. de Bitencourt, RM, Pamplona FA, Takahashi RN. A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. Neuropharmacology. 2013;64:389-395. doi:10.1016/j.neuropharm.2012.05.039 PubMed.
30. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162-165. doi:10.1016/j.drugalcdep.2013.12.08 PubMed.
31. Ahmed AI, van den Elsen, GA, Colbers A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-Tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl). 2015;232(14):2587-2595. doi:10.107/s0213-015-389-y PubMed.
32. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;(2):CD007204. PubMed.
33. Cougle JR, Bonn-Miller MO, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. 2011;25(3):554-558. doi:10.1037/a023076 PubMed.
34. Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011;25(3):485-491. doi:10.1037/a021945 PubMed.
35. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46(1):73-77. doi:10.1080/02791072.2013.873843 PubMed.
36. Boden MT, Babson KA, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22(3):277-284. doi:10.1/j.1521-0391.2012.12018.x PubMed.
37. Bordieri MJ, Tull MT, McDermott MJ, et al. The moderating role of experiential avoidance in the relationship between posttraumatic stress disorder symptom severity and Cannabis dependence. J Contextual Behav Sci. 2014;3(4):273-278. doi:10.1016/j.jcbs.2014.08.05 PubMed.
38. Earleywine M, Bolles JR. Marijuana, expectancies, and post-Traumatic stress symptoms: A preliminary investigation. J Psychoactive Drugs. 2014;46(3):171-177. doi:10.1080/02791072.2014.92018 PubMed.
39. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174-1180. doi:10.408/JCP.14m09475 PubMed.
40. van den Elsen, GA, Ahmed AI, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: A systematic review. Ageing Res Rev. 2014;14:56-64. doi:10.1016/j.ar.2014.01.07 PubMed.
41. Ahmed AI, van den Elsen GA, Colbers A, et al. Safety and pharmacokinetics of oral delta-9-Tetrahydrocannabinol in healthy older subjects: A randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(9):1475-1482. doi:10.1016/j.euroneuro.2014.06.07 PubMed.
42. Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23(1):116-117. doi:10.102/gps.1828 PubMed.
43. Maroof N, Pardon MC, Kendall DA. Endocannabinoid signalling in Alzheimer's disease. Biochem Soc Trans. 2013;41(6):1583-1587. doi:10.1042/BST20130140 PubMed.
44. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2(3):244-268. doi:10.1037/1064-1297.2.3.24.
45. Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction. 2008;103(3):439-449, discussion 450-451. doi:10.1/j.1360-043.207.02064.x PubMed.
46. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309 PubMed.
47. Aceto MD, Scates SM, Lowe JA, et al. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol. 1995;282(1-3):R1-R2. doi:10.1016/014-29(95)047-S PubMed.
48. Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol. 2001;416(1-2):75-81. doi:10.1016/S014-29(01)0873-1 PubMed.
49. Budney AJ, Moore BA, Vandrey RG, et al. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112(3):393-402. doi:10.1037/021-843X.12.3.393 PubMed.
50. Kouri EM, Pope HG Jr. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol. 2000;8(4):483-492. doi:10.1037/1064-1297.8.4.483 PubMed.
51. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642-649. doi:10.1038/mp.201.82 PubMed.
52. Sim-Selley LJ, Schechter NS, Rorrer WK, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-Term cannabinoid administration. Mol Pharmacol. 2006;70(3):986-996. doi:10.124/mol.105.019612 PubMed.
53. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-Tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-1572. doi:10.1038/sj.np.130496 PubMed.
54. Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483-1486. doi:10.1016/S0140-6736(87)92620-1 PubMed.
55. Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to pot-A review of the association between Cannabis and psychosis. Front Psychiatry. 2014;5:54. doi:10.389/fpsyt.2014.054 PubMed.
56. Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: A systematic meta-Analysis. Arch Gen Psychiatry. 2011;68(6):555-561. doi:10.101/archgenpsychiatry.201.5 PubMed.
57. Lev-Ran S, Roerecke M, Le Foll B, et al. The association between cannabis use and depression: A systematic review and metaanalysis of longitudinal studies. Psychol Med. 2014;44(4):797-810. doi:10.1017/S0329171301438 PubMed.
58. Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996;275(7):521-527. doi:10.101/jama.196.0353031027028 PubMed.
59. Pope HG Jr, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep. 2001;3(6):507-512. doi:10.107/s1920-01-045-7 PubMed.
60. Bolla KI, Brown K, Eldreth D, et al. Doserelated neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337-1343. doi:10.1212/01.WNL.03142.642.49 PubMed.
61. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657-E2664. doi:10.1073/pnas.1206820109 PubMed.
62. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: A review. Curr Drug Abuse Rev. 2008;1(1):81-98. doi:10.2174/18747371080101081 PubMed.
63. Meier MH, Hill ML, Small PJ, et al. Associations of adolescent cannabis use with academic performance and mental health: A longitudinal study of upper middle class youth. Drug Alcohol Depend. 2015;156:207-212. doi:10.1016/j.drugalcdep.2015.09.010 PubMed.
64. Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010. Am J Epidemiol. 2014;179(6):692-699. doi:10.1093/aje/kwt327 PubMed.
65. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-Analysis. BMJ. 2012;344:e536. doi:10.136/bmj.e536 PubMed.
66. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18(3):185-193. doi:10.1080/1050490902786934 PubMed.
67. Ronen A, Gershon P, Drobiner H, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40(3):926-934. doi:10.1016/j.ap.207.10.01 PubMed.
68. Ramaekers JG, Robbe HW, O'Hanlon JF. Marijuana, alcohol and actual driving performance. Hum Psychopharmacol. 2000;15(7):551-558. doi:10.102/109-107(2010)15:7<51:AID-HUP236>3.0.CO;2-PubMed.
69. Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. Expert Rev Respir Med. 2011;5(4):537-546, quiz 547. doi:10.1586/ers.1.40 PubMed.
70. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307(2):173-181. doi:10.101/jama.201.1961 PubMed.
71. Yamreudeewong W, Wong HK, Brausch LM, et al. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother. 2009;43(7):1347-1353. doi:10.1345/aph.1M064 PubMed.
72. Kosel BW, Aweeka FT, Benowitz NL, et al. The Effect of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002;16(4):543-550. doi:10.1097/02030-20203080-05 PubMed.
73. Hadland SE, Knight JR, Harris SK. Medical marijuana: Review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr. 2015;36(2):115-123. doi:10.1097/DBP.0129 PubMed.
74. Wang GS, Roosevelt G, Heard K. Pediatricmarijuana exposures in a medical marijuana state. JAMA Pediatr. 2013;167(7):630-633. doi:10.101/jamapediatrics.2013.140 PubMed 75.
75. Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial. Anesth Analg. 2010;110(2):604-610. doi:10.1213/ANE.0b013e3181c76f70 PubMed.
76. Miller FG, Wendler D, Swartzman LC. Deception in research on the placebo effect. PLoS Med. 2005;2(9):e262. doi:10.1371/journal.pmed.020262 PubMed